Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6):646-52.

Additional Metadata
Keywords Acromegaly, somatostatin, pegvisomant, pasireotide
Persistent URL dx.doi.org/10.20945/2359-3997000000195, hdl.handle.net/1765/123930
Journal Archives of endocrinology and metabolism
Citation
Coopmans, E.C. (Eva C.), van Meyel, S.W.F. (Sebastiaan W F), van der Lely, A-J, & Neggers, S.J.C.M.M. (Sebastian J C M M). (2019). The position of combined medical treatment in acromegaly. Archives of endocrinology and metabolism, 63(6), 646–652. doi:10.20945/2359-3997000000195